SCHEMBL6894916

SCHEMBL6894916

COC(=O)c1cccc2c1c1c(O)cc(-c3ccccc3)cc1n2Cc1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.45
TP53 P04637 3/20 0.45
PLA2G2A P14555 2/20 0.43
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
TNF P01375 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
NOD2 Q9HC29 1/20 0.40
NOD1 Q9Y239 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887896 0.94 MAPT (0.44) MAPTTP53PLA2G2AALDH1A1KMT2A
SCHEMBL6694644 0.89 AR (0.45) MAPTPLA2G2AALDH1A1KMT2AMEN1
SCHEMBL6897295 0.89 MAPT (0.48) MAPTTP53PLA2G2AALDH1A1KMT2A
SCHEMBL6894747 0.89 PLA2G2A (0.44) MAPTPLA2G2AALDH1A1KMT2AMEN1
SCHEMBL6891733 0.89 MAPT (0.43) MAPTPLA2G2AALDH1A1KMT2AMEN1
SCHEMBL6688455 0.88 MAPT (0.48) MAPTTP53PLA2G2AALDH1A1KMT2A
SCHEMBL6894204 0.88 L3MBTL1 (0.44) MAPTTP53ALDH1A1KMT2AMEN1
SCHEMBL6894500 0.88 PTGDR2 (0.39) TP53ALDH1A1KMT2AMEN1KDM4E
SCHEMBL6890571 0.88 MAPT (0.45) MAPTTP53PLA2G2AALDH1A1KMT2A
SCHEMBL6776614 0.88 PLA2G2A (0.44) PLA2G2AALDH1A1KMT2AMEN1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed